Geode Capital Management’s Werewolf Therapeutics HOWL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$324K Buy
389,487
+53,601
+16% +$36.7K ﹤0.01% 3745
2025
Q4
$213K Buy
335,886
+5,099
+2% +$6.2K ﹤0.01% 3883
2025
Q3
$652K Buy
330,787
+2,832
+0.9% +$3.88K ﹤0.01% 3526
2025
Q2
$358K Sell
327,955
-389,569
-54% -$401K ﹤0.01% 3660
2025
Q1
$698K Buy
717,524
+14,966
+2% +$19.6K ﹤0.01% 3428
2024
Q4
$1.04M Buy
702,558
+16,569
+2% +$33.8K ﹤0.01% 3365
2024
Q3
$1.45M Buy
685,989
+40,692
+6% +$92.6K ﹤0.01% 3224
2024
Q2
$1.57M Buy
645,297
+385,617
+148% +$1.85M ﹤0.01% 3177
2024
Q1
$1.68M Buy
259,680
+65,372
+34% +$381K ﹤0.01% 3180
2023
Q4
$750K Buy
194,308
+20,058
+12% +$51.2K ﹤0.01% 3458
2023
Q3
$373K Buy
174,250
+8,935
+5% +$24.6K ﹤0.01% 3717
2023
Q2
$504K Buy
165,315
+35,483
+27% +$99.9K ﹤0.01% 3638
2023
Q1
$338K Hold
129,832
﹤0.01% 3806
2022
Q4
$266K Buy
129,832
+9,545
+8% +$25K ﹤0.01% 3945
2022
Q3
$542K Buy
120,287
+41,007
+52% +$223K ﹤0.01% 3679
2022
Q2
$324K Sell
79,280
-209,025
-73% -$954K ﹤0.01% 3990
2022
Q1
$1.27M Buy
288,305
+74,081
+35% +$519K ﹤0.01% 3502
2021
Q4
$2.55M Buy
214,224
+77,752
+57% +$1.17M ﹤0.01% 3258
2021
Q3
$2.34M Buy
136,472
+28,294
+26% +$483K ﹤0.01% 3280
2021
Q2
$1.89M Buy
+108,178
New +$1.48M ﹤0.01% 3290

Other funds holding HOWL

Geode Capital Management's HOWL Position: Q1 2026 in Review

Geode Capital Management increased its Werewolf Therapeutics (HOWL) stake by 16% in Q1 2026, buying an estimated $36.7K and bringing the position to 389,487 shares worth $324K. The position accounts for ﹤0.01% of the portfolio, ranked #3745.

Geode Capital Management first reported a position in HOWL in Q2 2021 and has held it in 20 quarters since. The position peaked at $2.55M in Q4 2021. 48 funds tracked by Wall St. Rank hold HOWL as of Q1 2026.

  • Geode Capital Management held 389,487 shares of Werewolf Therapeutics worth $324K as of Q1 2026.
  • Geode Capital Management bought 53,601 Werewolf Therapeutics shares in Q1 2026, an estimated $36.7K.
  • Werewolf Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #3745 holding.
  • Geode Capital Management first reported a position in Werewolf Therapeutics in Q2 2021 and has held it in 20 quarters since.
  • Geode Capital Management's Werewolf Therapeutics position peaked at $2.55M in Q4 2021.
  • 48 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.